Hereditary angioedema treatment options: The availability of new therapies

Annals of Medicine

Volumn 44, Issue 6, 2012, Pages 523-529

  Aberer, Werner ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Acute treatment; Hereditary angioedema; Self administration

Indexed keywords

ANALGESIC AGENT; ANDROGEN; ANTIFIBRINOLYTIC AGENT; BRADYKININ B2 RECEPTOR; CEBITOR; CETOR; COMPLEMENT COMPONENT C1S INHIBITOR; DANAZOL; ECALLANTIDE; FRESH FROZEN PLASMA; ICATIBANT; KALLIKREIN INHIBITOR; STANOZOLOL; TRANEXAMIC ACID; UNCLASSIFIED DRUG;

ABDOMINAL DISEASE; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; AUTOSOMAL DOMINANT DISORDER; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DYSPEPSIA; EUROPEAN UNION; FATIGUE; HEADACHE; HUMAN; HYPOTENSION; LICENSING; LIVER TOXICITY; MENSTRUAL IRREGULARITY; MUSCLE CRAMP; MUSCLE WEAKNESS; MYALGIA; NANOFILTRATION; NONHUMAN; PASTEURIZATION; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RETINA DISEASE; REVIEW; SIDE EFFECT; SKIN EDEMA; SOCIAL INSURANCE; UPPER RESPIRATORY TRACT; VIRILIZATION; VIRUS TRANSMISSION; WEIGHT GAIN;

AIRWAY OBSTRUCTION; ANGIOEDEMAS, HEREDITARY; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BRADYKININ; COMPLEMENT C1 INHIBITOR PROTEIN; COSTS AND COST ANALYSIS; EUROPE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HOSPITALIZATION; HUMANS; INSURANCE COVERAGE; INSURANCE, PHARMACEUTICAL SERVICES; LEGISLATION, DRUG; PEPTIDES; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; SELF ADMINISTRATION;

EID: 84865615187     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2012.687833     Document Type: Review

References (40)

1. Agostoni A, Aygören-Pürsün E, Binkley KE, Blanch A, Bork K, Bouillet L, et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol. 2004;114:S51-131. (Pubitemid 39200689)
2. Kaplan AP, Joseph K. The bradykinin-forming cascade and its role in hereditary angioedema. Ann Allergy Asthma Immunol. 2010;104:193-204.
3. Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A. Plasma bradykinin in angio-oedema. Lancet. 1998;351:1693-7. (Pubitemid 28254530)
4. Weis M. Clinical review of hereditary angioedema: diagnosis and management. Postgrad Med. 2009;121:113-20.
5. Nzeako UC, Frigas E, Tremaine WJ. Hereditary angioedema: a broad review for clinicians. Arch Intern Med. 2001;161:2417-29. (Pubitemid 33043115)
6. Bracho FA. Hereditary angioedema. Curr Opin Hematol. 2005;12:493-8. (Pubitemid 41546482)
7. Bygum A, Andersen KE, Mikkelsen CS. Self-administration of intravenous C1-inhibitor therapy for hereditary angioedema and associated quality of life benefits. Eur J Dermatol. 2009;19:147-51.
8. Wilson DA, Bork K, Shea EP, Rentz AM, Blaustein MB, Pullman WE. Economic costs associated with acute attacks HAE: the availability of new therapies 529 and long-term management of hereditary angioedema. Ann Allergy Asthma Immunol. 2010;104:314-20.
9. Lumry WR, Castaldo AJ, Vernon MK, Blaustein MB, Wilson DA, Horn PT. The humanistic burden of hereditary angioedema: impact on health-related quality of life, productivity, and depression. Allergy Asthma Proc. 2010;31:407-14.
10. Roche O, Blanch A, Caballero T, Sastre N, Callejo D, López- Trascasa M. Hereditary angioedema due to C1 inhibitor deficiency: patient registry and approach to the prevalence in Spain. Ann Allergy Asthma Immunol. 2005;94:498-503. (Pubitemid 40547939)
11. Lunn ML, Santos CB, Craig TJ. Is there a need for clinical guidelines in the United States for the diagnosis of hereditary angioedema and the screening of family members of affected patients? Ann Allergy Asthma Immunol. 2010;104:211-4.
12. Longhurst HJ, Farkas H, Craig T, Aygören-Pürsün E, Bethune C, Bjorkander J, et al. HAE international home therapy consensus document. Allergy Asthma Clin Immunol. 2010;6:22.
13. Zuraw B, Yasothan U, Kirkpatrick P. Ecallantide. Nat Rev Drug Discov. 2010;9:189-90.
14. Bowen T, Cicardi M, Farkas H, Bork K, Longhurst HJ, Zuraw B, et al. International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol. 2010;6:24.
15. De Serres J, Gröner A, Lindner J. Safety and efficacy of pasteurized C1 inhibitor concentrate (Berinert P) in hereditary angioedema: a review. Transfus Apher Sci. 2003;29:247-54. (Pubitemid 37321355)
16. Cicardi M, Levy RJ, McNeil DL, Li HH, Sheffer AL, Campion M, et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med. 2010;363:523-31.
17. Kalbitor prescribing information. Available from: http://www.kalbitor. com/pdf/KalbitorFullPrescribingInformation.pdf (accessed 15 July 2011).
18. Craig TJ, Levy RJ, Wasserman RL, Bewtra AK, Hurewitz D, Obtulowicz K, et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol. 2009;124:801-8.
19. Wasserman RL, Levy RJ, Bewtra AK, Hurewitz D, Craig TJ, Kiessling PC, et al. Prospective study of C1 esterase inhibitor in the treatment of successive acute abdominal and facial hereditary angioedema attacks. Ann Allergy Asthma Immunol. 2011;106:62-8.
20. Zuraw BL, Busse PJ, White M, Jacobs J, Lumry W, Baker J, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med. 2010;363:513-22.
21. Zuraw B, Cicardi M, Levy RJ, Nuijens JH, Relan A, Visscher S, et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol. 2010;126:821-7.e14.
22. Cicardi M, Banerji A, Bracho F, Malbrán A, Rosenkranz B, Riedl M, et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med. 2010;363:532-41.
23. Lumry WR, Li HH, Levy RJ, Potter PC, Farkas H, Moldovan D, et al. Randomized placebo-controlled trial of the bradykinin B2 receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. Ann Allergy Asthma Immunol. 2011;107:529-37.
24. Levy RJ, Lumry WR, McNeil DL, Li HH, Campion M, Horn PT, et al. EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol. 2010;104:523-9.
25. Gompels MM, Lock RJ, Abinun M, Bethune CA, Davies G, Grattan C, et al. C1 inhibitor deficiency: consensus document. Clin Exp Immunol. 2005;139:379-94. (Pubitemid 40333248)
26. Cyklokapron summary of product characteristics. Available from: http://www.medicines.org.uk/emc/medicine/16512/SPC/(accessed 17 August 2011).
27. Caballero T, Farkas H, Bouillet L, Bowen T, Gompel A, Fagerberg C, et al. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. J Allergy Clin Immunol. 2012;129:308-20.
28. Cinryze summary of product characteristics. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/001207/WC500108895.pdf (accessed 15 July 2011).
29. Berinert prescribing information. Available from: http://www.berinert. com/docs/Berinert-pi.pdf (accessed 15 July 2011).
30. Cetor summary of product characteristics. Available from: http://www.sanquin. nl/sanquin-eng/sqn-products-plasma.nsf/All/F197E/ $FILE/common-spc-summaryofproductcharacteristicscetor500uen.pdf (accessed 15 July 2011).
31. Ruconest summary of product characteristics. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/001223/WC500098542.pdf (accessed 15 July 2011).
32. Firazyr summary of product characteristics. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000899/WC500022966.pdf (accessed 15 July 2011).
33. Craig T, Katelaris C, Longhurst H, Grumach A, Maurer M. Hereditary angioedema worldwide epidemiology and treatment practices: interim results of a WAO survey. Allergy. 2011;66(Suppl 94):1-104. (Abstract no. 164).
34. Cicardi M, Bork K, Caballero T, Craig T, Li HH, Longhurst H, et al. Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy. 2012;67:147-57.
35. Riedl M, Gower RG, Chrvala CA. Current medical management of hereditary angioedema: results from a large survey of US physicians. Ann Allergy Asthma Immunol. 2011;106:316-22.e4.
36. Longhurst HJ, Carr S, Khair K. C1-inhibitor concentrate home therapy for hereditary angioedema: a viable, effective treatment option. Clin Exp Immunol. 2007;147:11-17. (Pubitemid 44915550)
37. Levi M, Choi G, Picavet C, Hack CE. Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency. J Allergy Clin Immunol. 2006;117:904-8.
38. Rusicke E, Martinez-Saguer E, Aygören-Pürsün E, Kreuz W. Home treatment in patients with hereditary angioedema (HAE). J Allergy Clin Immunol. 2006;117:S180. (Abstract no. 700).
39. Gabriel J. Infusion therapy. Part two. Prevention and management of complications. Nurs Stand. 2008;22:41-8.
40. Dagen C, Craig TJ. Treatment of hereditary angioedema: items that need to be addressed in practice parameter. Allergy Asthma Clin Immunol. 2010;6:11.